A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma — FIGHT-302

Metastatic Cholangiocarcinoma Clinical Trial

Official title:
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03656536
Study type	Interventional
Source	Incyte Corporation
Contact	Incyte Corporation Call Center (US)
Phone	1.855.463.3463
Email	medinfo@incyte.com
Status	Recruiting
Phase	Phase 3
Start date	June 3, 2019
Completion date	July 27, 2028

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03250273` - A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma	Phase 2
Recruiting	`NCT06160752` - Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations	Phase 1
Recruiting	`NCT06420349` - NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma	Phase 1
Active, not recruiting	`NCT04175912` - Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver	Phase 2
Terminated	`NCT04088188` - Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma	Phase 1
Completed	`NCT03201458` - Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer	Phase 2
Completed	`NCT02989857` - Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)	Phase 3
Recruiting	`NCT06178588` - Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma	Phase 2
Terminated	`NCT02757391` - CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors	Phase 1